AMNI.ST
Amniotics AB (publ) [AMNI.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AMNI.ST Stock Summary
In the News
AMNI.ST Financial details
Company Rating
-
Market Cap
10.57M
Income
-31.13M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
22 Feb 2024
P/E
-0.01
Forward P/E
-
PEG
-0
P/S
-
P/B
0.19
P/C
-
P/FCF
-0.33
Quick Ratio
0.17
Current Ratio
0.48
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.37
EPS next Y
-
EPS next Q
-
EPS this Y
-77.47%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-96.67%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-172%
ROE
-677%
ROC
-15.95%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0022-0.0456
52W High
-
52W Low
-
RSI
-
Rel Volume
0.28
Avg Volume
24.76M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.621
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 24.76M
- Market Capitalization 10.57M
- Employee 6
- CEO Mr. Marcus Larsson Ph.D.
- Headquarters Lund,SE
- IPO Date 2021-07-06
-
Website
https://www.amniotics.com 
Amniotics AB (publ) develops, manufactures, and sells stem cell therapies based on mesenchymal stem cells to treat severe life-threatening diseases. The company's lead drug candidate is PulmoStem for the treatment of inflammatory and fibrotic lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; and CutiStem for the treatment of dermatological indications. The company offers contract development and contract manufacturing services for advanced therapy medicinal products to the pharmaceutical industries, universities, and hospitals. Amniotics AB (publ) was incorporated in 2015 and is based in Lund, Sweden.
